Soleus Capital Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Soleus Capital Management's NRIX Position: Q3 2026 in Review
Soleus Capital Management reduced its Nurix Therapeutics (NRIX) stake by 39% in Q3 2026, selling an estimated $14.3M and leaving 892,163 shares worth $21.2M. The position accounts for 0.75% of the portfolio, ranked #30.
Soleus Capital Management first reported a position in NRIX in Q3 2021 and has held it in 18 quarters since. The position peaked at $42.9M in Q2 2024. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Soleus Capital Management held 892,163 shares of Nurix Therapeutics worth $21.2M as of Q3 2026.
- Soleus Capital Management sold 573,000 Nurix Therapeutics shares in Q3 2026, an estimated $14.3M.
- Nurix Therapeutics made up 0.75% of Soleus Capital Management's portfolio in Q3 2026, its #30 holding.
- Soleus Capital Management first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 18 quarters since.
- Soleus Capital Management's Nurix Therapeutics position peaked at $42.9M in Q2 2024.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.